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ABSTRACT
Anterior gradient 2 (AGR2) is a cancer-associated secreted protein found 
predominantly in adenocarcinomas. Given its ubiquity in solid tumors, cancer-secreted 
AGR2 could be a useful biomarker in urine or blood for early detection. However, 
normal organs express and might also secrete AGR2, which would impact its utility 
as a cancer biomarker. Uniform AGR2 expression is found in the normal bladder 
urothelium. Little AGR2 is secreted by the urothelial cells as no measurable amounts 
could be detected in urine. The urinary proteomes of healthy people contain no listing 
for AGR2. Likewise, the blood proteomes of healthy people also contain no significant 
peptide counts for AGR2 suggesting little urothelial secretion into capillaries of the 
lamina propria. Expression of AGR2 is lost in urothelial carcinoma, with only 25% 
of primary tumors observed to retain AGR2 expression in a cohort of lymph node-
positive cases. AGR2 is secreted by the urothelial carcinoma cells as urinary AGR2 
was measured in the voided urine of 25% of the cases analyzed in a cohort of cancer 
vs. non-cancer patients. The fraction of AGR2-positive urine samples was consistent 
with the fraction of urothelial carcinoma that stained positive for AGR2. Since cancer 
cells secrete AGR2 while normal cells do not, its measurement in body fluids could 
be used to indicate tumor presence. Furthermore, AGR2 has also been found on the 
cell surface of cancer cells. Taken together, secretion and cell surface localization of 
AGR2 are characteristic of cancer, while expression of AGR2 by itself is not.
INTRODUCTION
Anterior gradient 2 (AGR2) is an adenocarcinoma 
antigen with elevated expression in many solid tumor 
types including prostate, breast, pancreatic, gastro-
intestinal, lung. The protein is a protein disulfide isomerase 
(PDI) found in the endoplasmic reticulum (ER) where it 
functions as a molecular chaperone in protein folding [1]. 
The ER could have an important role in carcinogenesis 
and tumor biology [2]. A non-canonic ER retention motif 
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(C-terminal KTEL) in AGR2 may be responsible for the 
diverse trafficking of this molecule [3]. In addition to the 
ER, AGR2 can be shunted to the nucleus, cell surface or 
extracellular space. Secreted AGR2 can function to trigger 
cellular differentiation in responding cells as documented 
in salamander limb regeneration [4]. AGR2 is secreted as 
a 19 kDa protein by prostate cancer cells measurable at pg/
ml levels in the urine [5], and blood [6] of patients. AGR2 
was identified as a biomarker candidate in prostate cancer 
by comparative transcriptomic analysis of sorted CD26+ 
cancer cells vs. CD26+ luminal cells [7]. In this approach, 
genes with elevated expression encoding secreted proteins 
in cancer are considered to be viable candidates; genes 
expressed by both cancer and normal cell types are not, 
and are thus ignored. A further consideration is that AGR2 
expressed in the cancer of one organ could be expressed 
in the normal tissue of other organs, which would impact 
its utility as a biomarker. There would be very few cancer-
specific biomarkers based on expression difference if 
examined systematically between cancer and all normal 
tissue. This is not unexpected since every gene in the 
genome serves a useful function in some cell types. AGR2 
is secreted by pancreatic cancer cells [8], and localized 
on the cell surface of pancreatic cancer cells [9]. Whether 
normal AGR2-positive cells also secrete or express this 
protein on the cell surface is not known. Both normal 
prostate and pancreatic epithelial cells do not express 
AGR2 [7, 9].
In this study, urinary bladder expression of AGR2 
was investigated. Cell-type transcriptomes previously 
indicated that CD9+ urothelial cells were positive for 
AGR2 expression [10]. The entire urothelium was 
immunostained positive for AGR2. However, AGR2 was 
not observed to be secreted by the urothelial cells as little 
of this protein was detected in urine [5, 6]. This finding 
was supported by database query of urine proteomes 
containing urinary proteins identified by large-scale 
mass spectrometry proteomics. Database query of blood 
proteomes similarly indicated little AGR2 in circulation 
as, for example, from secretion by urothelial cells into 
capillaries within the underlying lamina propria. AGR2 
expression is lost in urothelial carcinoma, but a minority 
of bladder tumors were found to retain AGR2. The 
detection of AGR2 in the urine of a subset of bladder 
cancer patients indicates that AGR2 could be secreted by 
urothelial carcinoma cells. The take home message is that 
differential subcellular localization or protein address of 
AGR2 – cell interior vs. cell exterior – not expression, 
makes AGR2 a cancer biomarker. This may reflect the 
different functional roles played by AGR2 in normal cells 
vs. cancer cells. Such localization differences appear to be 
a property of PDI enzymes [11]. Cell surface expression 
could be inhibited by Brefeldin A [12]. In clinical utility, 
AGR2+ cancer cells can be targeted for eradication by 
agents such as antibodies or antibody drug conjugates, 
while AGR2+ normal cells would be spared.
RESULTS
Expression of AGR2 by urothelial cells
The normal bladder urothelium was uniformly 
immunostained for AGR2 at moderate intensity as shown 
in Figure 1A. Immunostaining of prostate cancer cells was 
comparatively more intense [13, 14]. This immunostaining 
confirmed the gene expression detected by DNA 
microarray analysis of sorted CD9+ urothelial cells. Both 
paraffinized sections stained with polyclonal anti-AGR2 
and frozen sections stained with monoclonal anti-AGR2 
showed that the two antibodies recognized the same cell 
types. Urothelial AGR2 expression was recorded in five 
benign tissue specimens. Urothelial AGR2 expression was 
40 times lower than prostate cancer AGR2 expression as 
calculated from the array signal intensity values for AGR2 
in CD9+ urothelial cells and sorted CD26+ prostate cancer 
cells (Figure 1B). A good correlation between array signal 
values and immunostaining intensity in our biomarker 
study was reported previously [15]. Values for the 
selected reference genes were all found to be equivalent. 
In addition, the observation of faint AGR2 staining of 
the stroma (in frozen sections) next to the prostate tumor 
glands could be used to indicate that AGR2 was secreted 
[14]. No such staining was seen in the stroma adjacent to 
the urothelium (Figure 1A) suggesting that AGR2 was not 
secreted by the urothelial cells.
Bladder cancer expression of AGR2
AGR2 expression in bladder cancer was examined 
in a cohort of patients with lymph node involvement. In 
129/152 evaluable spots of tissue taken from the centers 
of primary tumors, 24% showed AGR2 immunostaining, 
whereas in 124/152 evaluable spots taken from the tumor 
invasion fronts, 12% showed AGR2 immunostaining. 
Examples of AGR2 tumor immunostaining are shown 
in Figure 2. In many cases, the cancer staining appeared 
stronger than that of normal urothelial cells. Thus, in a 
majority of analyzed bladder cancer cases, malignant 
transformation was accompanied by a loss of urothelial 
AGR2. The microarray result of sorted CD9+ cancer cells 
from one bladder tumor specimen showed no AGR2 
expression (Figure 1B), but showed CD10 expression 
(Figure 1B). CD10 was investigated because of its 
importance in lymph node spread of prostate cancer cells, 
and its diametrically opposite role to that of AGR2 in the 
local vs. distal spread of tumor [16]. Most AGR2+ prostate 
cancer cells were negative for CD10 [14]. Normal AGR2+ 
urothelial cells also showed no CD10 expression [10].
In 125/152 and 121/152 evaluable spots of lymph 
node metastases on two TMA, 44% showed AGR2 
staining, examples of which are shown in Figure 3. 
There were instances in which AGR2 staining was not 
detected in the primary tumor but was detected in the 
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Figure 1: Bladder AGR2 expression. A. The urothelial cells in specimen 03-043B1 are stained at moderate intensity (compared 
with that in prostate cancer cells) by anti-AGR2. Two different parts of the tissue specimen show uniform expression likely throughout the 
urothelium. Magnification is 100x. B. Transcriptome dataset query display compares the expression levels of AGR2 and reference genes in 
sorted populations of prostate cancer cells (05-179_CD26t), bladder cancer cells (07-008_CB_epi_CD9posi), and normal bladder cells (07-
015_NB_epi_CD9posi). The same data is shown below in a histogram format – CP = prostate cancer; CB = bladder cancer; NB = normal 
bladder. Probeset intensity values are on the y-axis.
Figure 2: AGR2 in primary bladder cancer. Shown are TMA examples of tumor immunostaining for AGR2. Positive cells are in 
brown.
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corresponding lymph nodes (e.g., cases B97-05, B00-08, 
B05-05, Supplementary Table 1). Many of the primary 
tumors showing AGR2 staining also showed AGR2-
positive lymph nodes. McNemar’s test with Yates’ 
correction for continuity for this distribution of AGR2 
positivity between primary tumors and lymph node 
metastases was χ2 = 9.24 (P = <0.01).
There was no correlation observed between patient 
survival and AGR2 expression: P = 0.475 for AGR2+ 
tumor center, P = 0.387 for AGR2+ invasion front in a 
univariate analysis; P = 0.39 and 0.73, respectively, in 
a multivariate analysis. In contrast, capsule perforation 
plus age, gender, and pT stage were significant predictors 
of survival in agreement with our previous study results 
[17]. When the patients were divided into >10 y survival 
groups (n = 10, 6.6%) and <1 y survival (n = 42, 27.8%), 
most of the long survival cases (in spite of their positive 
lymph node status) showed absent or low AGR2 staining 
in the primary tumor with the exception of case B94-01 
(Supplementary Table 1). Although B94-01 was staged 
pT4 and pN2, there was no capsule perforation, which was 
the best indicator of survival. In the poor survival group, 
both AGR2+ and AGR2− tumors were observed.
Urinary AGR2
Voided urine samples from two healthy female 
donors (B-A and B-B) collected on different days were 
assayed for AGR2. The levels of AGR2 observed in 
both urine samples were close to the buffer background 
(Figure 4). The positive control of collagenase digestion 
media of prostate cancer xenograft LuCaP 23.12 tumor 
contained a level of AGR2 at 25-fold higher than that 
of the buffer. High AGR2 expression in LuCaP 23.12 
was previously shown by immunostaining and DNA 
array analysis [14]. Despite the entire urothelium being 
positive for its expression, little of the small 19 kDa 
AGR2 was released by the bladder into urine. No AGR2 
was detectable by Western blotting of urine samples 
[13]. This conclusion was supported by urine proteome 
database queries. No match was found for AGR2 in the 
UrinePA-PeptideAtlas of 2,500 proteins identified by 
proteomics. AGR2 was not found in the core urinary 
proteome of healthy people. Queries of other recently 
published normal urine proteomes (e.g., ref. 18) also 
revealed no data entry for AGR2. For comparison, 
UPK3A (uroplakin) from bladder cells had 2 identifiers 
in 3 builds, and was observed ≥3 times (for an abundant 
non-secreted structural protein); UMOD (uromodulin) 
from kidney cells had 15 identifiers in 3 builds, and 
was observed ≥24,115 times; ALB (albumin) had 18 
identifiers in 3 builds, and was observed ≥33,149 times. 
The times observed could be used as an indicator of 
relative abundance. UMOD and ALB were two of 
the most abundant urinary proteins identifiable by gel 
electrophoresis separation and mass spectrometry of 
excised protein bands [19]. In Figure 4, urine from a 
bladder cancer patient B13-026 was tested, and the level 
of AGR2 was found to be 7.5-fold higher than buffer 
(note that tumors generally involve only a small part of 
the urothelium). This suggested that urothelial carcinoma 
cells could secrete AGR2.
Urine from a cohort of 20 non-cancer (NB) and 20 
cancer (CB) patients (Supplementary Table 2) was tested 
Figure 3: AGR2 in lymph node metastases. Shown are TMA examples of lymph node immunostaining for AGR2. The amount of 
cancer cells is variable in the specimen cores taken for the tissue array.
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for AGR2 by ELISA (Figure 5). Using the OD405 value 
for PC3 positive control as a reference, the majority of 
non-cancer samples were below the reference value, with 
only 3 (15%) exhibiting higher values. AGR2 in these 
samples could be due to breakdown of released urothelial 
cells from normal tissue turnover. In contrast, 5 cancer 
samples (25%) scored well above the PC3 reference 
value, a frequency that was expected given the percentage 
of primary urothelial carcinoma being positive for AGR2 
as determined above. These results suggested that AGR2 
was secreted by bladder cancer cells and not by normal 
urothelial cells, despite both cell types expressing AGR2 
(P = 0.012). The AUC for this cohort analysis was 0.73. 
Two of the five urine positive cases (40%) suffered 
recurrence as did two of the urine negative cases (13%).
DISCUSSION
Unlike the prostate and pancreas where AGR2 is 
up-regulated in cancer cells compared to normal cells, 
AGR2 is down-regulated in a majority of bladder cancer 
cells compared to normal bladder cells. AGR2 expression 
in normal urothelial cells is comparatively lower than 
that in prostate cancer cells. Increased AGR2 expression 
is also found in bladder tumors. Significantly, AGR2 is 
not secreted by urothelial cells as no large amounts could 
be detected in the urine of healthy people by sensitive 
methods such as ELISA and targeted proteomics to pg/
ml levels. The proteome of normal urine contains no 
AGR2. The urothelium also does not secrete AGR2 into 
blood vessels of the lamina propria as little AGR2 was 
detected by targeted proteomics in the blood of healthy 
people [6]. Normal lung epithelium is also positive 
for AGR2 expression [20]. The lung, like the bladder, 
apparently does not secrete large amounts of AGR2 
into circulation. Otherwise, a substantial level could be 
measured in blood. High serum AGR2 levels in the ng/
ml range reported in the literature were determined by 
a commercial ELISA based on polyclonal antibodies 
of suspect specificity [21]. These antibodies detected 
AGR2 expression in prostate neuroendocrine small 
cell carcinoma, which was shown by our monoclonal 
Figure 4: Urinary AGR2 levels in healthy women. A. In the histogram, OD405 readings are on the y-axis for the samples listed on 
the x-axis. B-A1 to B-A7 are seven donations from female subject A (the prefix B is for “bladder” subject urine vs. P for “prostate” subject 
urine); B-B1 to B-B8 are eight donations from female subject B. The red line marks the highest level (B-A4) measured for these non-cancer 
urine. LuCaP 23.12 is the cell-free tissue digestion media of the prostate cancer xenograft. B13-026 is the urine from a bladder cancer 
patient. B. In the boxplot, the 25 and 75 percentile values and the medians are shown. The standard deviation (SD) values are shown using 
whiskers. For comparison, the values for LuCaP 23.12 and B13-026 are included.
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antibodies and DNA arrays to be negative for AGR2 [14]. 
Targeted proteomics does not have the disadvantage of 
cross-reactivity in antibodies, and peptide identification is 
based on unique sequences. AGR2 secretion appears to 
be a characteristic of cancer cells. Normal bladder non-
secretion of AGR2 makes urinary AGR2 measurement 
a viable test to detect prostate cancer [5]. Different 
subcellular localization could be due to different AGR2 
isoforms, which could result from alternative splicing 
[22] or differential post-translational modifications. A 
candidate splice variant (with a deleted C-terminal KTEL), 
however, encodes a much smaller protein missing multiple 
exons. Alternatively, overexpression of AGR2 in cancer 
cells could saturate the KDEL receptors in the ER causing 
the excess protein molecules to be exported. To understand 
the precise mechanism likely requires purification of the 
protein from cancer cell cultures for comparison to that 
purified from normal tissue cells. This cancer specificity 
would make AGR2 an attractive tumor-associated antigen 
for therapeutic targeting. In a biodistribution study using 
radiolabeled anti-AGR2 monoclonal antibody P3A5, an 
implanted murine Agr2+ pancreatic tumor was specifically 
labeled whereas the bladder, lung (and pancreas) were not 
(unpublished data of Drs. Laurent Dumartin and Tatjana 
Crnogorac-Jurcevic, Queen Mary University of London). 
The anti-human AGR2 P3A5 also recognizes murine 
Agr2 as the two proteins are highly similar. The result 
demonstrated absence of cell surface Agr2 in normal cells. 
With regard to the function of cancer-secreted AGR2, the 
addition of AGR2-containing media to cultured prostate 
stromal cells showed that these cells were induced to 
undergo programmed cell death with cellular blebbing, 
cell shrinkage, and chromosomal DNA fragmentation. 
These features were not observed in media containing 
no AGR2, or when P3A5 was co-added to the media 
(unpublished data). It is possible that large amounts of free 
AGR2 in circulation would have a deleterious effect on 
normal tissue cells.
Bladder tumor AGR2 expression in the TMA 
cohort was not correlated with patient survival, unlike 
what has been found in prostate and lung cancer [13, 
22]. Both AGR2+ and AGR2− tumors were found in 
cases of short survival, although nearly all of the few 
long surviving patients with lymph node involvement 
had AGR2− tumors. Previous limited studies using qRT-
PCR, which did not pinpoint the expression location, 
Figure 5: Urinary AGR2 levels in bladder cancer patients. A. The x-axis and y-axis are the same as those in Figure 4. Samples 
labeled NB are non-cancer (n = 20), CB are cancer (n = 20). The red line marks the level of positive control PC3 and the blue line the level 
of negative buffer control. Red dots indicate cases with recurrence. B. The boxplot is shown with the 25 and 75 percentile values and the 
medians, 1.5xSD values in whiskers. P = 0.012. C. Shown is the AUC = 0.73.
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showed under-expression of AGR2 in bladder tumors, 
and no correlation with progression or survival [23]. 
Patients with AGR2 positive lymph nodes did not show 
lower survival [24]. A trend towards a higher percentage 
of AGR2+ lymph nodes suggests that AGR2-expressing 
cancer cells could possess a greater potential for local 
spread. AGR2 expression was up-regulated in a gastric 
cancer cell subline with high metastatic potential 
for invasion of lymph nodes [25]. In prostate cancer 
spread to regional lymph nodes, however, CD10 is 
more involved than AGR2 [26]. A correlation between 
higher grade and cancer progression was also reported 
for CD10+ bladder tumors [27, 28], although CD10 
expression in our TMA cohort was previously found 
to correlate with a more favorable outcome [29]. The 
AGR2− tumor cells of the bladder cancer profiled by 
our array analysis were positive for CD10. Bladder 
cancer cells, like prostate cancer cells, could be sorted 
into different AGR2/CD10 phenotypes for survival 
correlation [14]. For example, AGR2highCD10low 
would correspond to a different outcome than 
AGR2highCD10high. Much larger cohort studies involving 
over 1,000 cases, which can be difficult to obtain as 
bladder cancer is not common, as done in prostate cancer 
regarding cancer expression of CD10 [30] are needed 
to resolve the divergent conclusions reported in the 
literature. Interestingly, distinct subcellular expression 
patterns of CD10 (cell surface vs. cytoplasmic) were 
found to be associated with prostate tumor grade 
[30]. CD10 cytoplasmic expression could lead to new 
functions through novel interactions with other proteins 
such as HSP27 and HSP70 [31]. Differential subcellular 
localization of protein molecules shown by both AGR2 
(cell interior to cell exterior) and CD10 (cell exterior to 
cell interior) could well be a property of cancer cells. 
Cell surface or secreted AGR2 likely could also interact 
with other proteins (e.g., CD10, a cell surface peptidase) 
to generate new functions. Whether AGR2+ tumor 
cells predominate in the late stages of bladder cancer 
like prostate cancer [14] remains to be determined. 
This would require harvesting tumor metastases in 
advanced diseases as reported by our group for prostate 
cancer [32].
MATERIALS AND METHODS
Patient materials and ethics statement
This study was approved by the Institutional 
Review Boards of the University of Washington, the 
University of California, Los Angeles, the University of 
Bern, Switzerland, and the University of Hawaii. Written 
informed consent for individual patients was obtained for 
the use of urine and tissue samples in this research.
AGR2 immunohistochemistry and bladder tissue 
microarrays
OCT-frozen benign bladder tissue obtained from 
surgery at the University of Washington was processed 
for staining with mouse monoclonal anti-AGR2 clone 
P1G4 (IgG1) at 1:30 [5]. Negative control was stained 
with concentration-matched non-immune IgG. AGR2 
expression in cancer was evaluated on tissue microarrays 
(TMA) constructed from primary tumor (each specimen 
consisted of samplings of tumor center and invasion 
front) and corresponding lymph node metastases [29]. 
These tumor samples were obtained from 152 lymph 
node-positive bladder cancer cases that were treated by 
cystectomy and pelvic lymphadenectomy at the University 
of Bern. TMA were immunostained with rabbit polyclonal 
ab43043 (abcam, Cambridge, MA) at 1:30 following 
antigen retrieval [13]. Each stained tissue core was 
examined by a pathologist (LDT), photographed and 
AGR2 expression was recorded numerically: 1 for weak, 2 
for moderate, 3 for strong; plus the percentages of staining 
as described [13].
AGR2 expression levels in bladder cells vs. 
prostate cancer cells
Transcriptome datasets of sorted CD9+ urothelial 
cells [10] and CD26+ prostate cancer cells [7] were 
queried for intensity values of AGR2 (i.e., virtual 
Northern blot analysis). The values of AGR2 and 
reference housekeeping genes [33] aminolevulinate 
synthase (ALAS1), β-2-microglobulin (B2M), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
hypoxanthine phosphoribosyl transferase (HPRT1), 
tubulin (TUBA1) as well as MME (CD10) for 
comparison were downloaded from the respective 
transcriptome datasets archived in our public database 
http://scgap.systemsbiology.net/data/. The values were 
displayed on a gray scale.
Bladder cancer AGR2 expression and clinical 
outcomes
AGR2 expression was correlated with tumor 
characteristics (stage, extracapsular extension, number 
and total diameter of metastases) and survival. Briefly, 
non-parametric two-group and multi-group comparisons 
were carried out by Mann-Whitney and Kruskal-Wallis 
tests, and correlations by Spearman Correlation. The 
Cox proportional hazards model was used for statistical 
significance of predictors in both a univariate and 
a multivariate setting. All statistical analyses were 
performed with StatView Version 5.0 (SAS Institute) or 
software package R (http://www.r-project.org).
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AGR2 ELISA of voided urine
Urine samples were collected from two young 
female donors on separate days. The supernatant was 
desalted and concentrated by Amicon filters (Millipore, 
Billerica, MA) [5]. An amount of 30-50 ml was 
concentrated to 600-1,000 μl in 50 mM NH4HCO3 for 
measurement of AGR2. The sandwich ELISA was based 
on generated monoclonal antibodies P1G4 (IgG1) and 
P3A5 (IgG2a) [5]. Purified P1G4 (1:1,000) was used 
to coat BD Falcon Flexible plates (BD Biosciences, 
Mountainview, CA) in phosphate-buffered saline (PBS). 
The blocking solution contained 1% BSA in PBS, and the 
urine samples were added at 4° for overnight incubation. 
Purified P3A5 (1:1,000) was used for detection with 
horse radish peroxidase (HRP)-conjugated anti-mouse 
IgG2a and chromogenic substrate 3,3’-diaminobenzidine 
(DAB). Recombinant AGR2 (rAGR2, GenWay Biotech, 
San Diego, CA), which was recognized by the antibodies, 
was employed for calibration. Urine samples from bladder 
cancer patients were collected during clinical visits (at the 
University of Hawaii Cancer Center), frozen at -80°, and 
shipped to UW. The exclusion criteria for male bladder 
cancer patients included no concurrent prostate cancer 
diagnosis. The cell-free supernatant of tissue digestion 
media of the AGR2+ prostate cancer xenograft LuCaP 
23.12 tumor [14] and the media of cultured AGR2+ prostate 
cancer cell line PC3 [5] were used as positive control. For 
ELISA data presentation, OriginPro 2015 (http://www.
originlab.com) was used to draw boxplots. The P-value 
was calculated using the non-parametric Wilcoxon-Mann-
Whitney test in OriginPro 2015. The receiver operating 
characteristic (ROC) curve was generated to represent the 
trade-off between the false positive rates and true positive 
rates for every possible cutoff value. The confidence 
level was at 95%. The area under the curve (AUC) was 
calculated with OriginPro 2015.
Urine proteome database query
The human urine proteome datasets archived 
in PeptideAtlas (http://www.peptideatlas.org) were 
interrogated for mass spectrometry data entries. The 
UrinePA build contained high confidence peptide and 
protein identifications from five different labs including 
ours [34]. It contained 2,500 non-redundant proteins 
cataloged at 1% false discovery rate. A sub-database 
listed 587 entries of the “Core Urinary Proteome”, which 
was established from analysis of second morning urine 
collected over three days from seven young healthy 
volunteers [35].
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